Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sunho Biologics,Inc. ( (HK:2898) ) has shared an announcement.
Sunho Biologics, Inc. has issued a supplemental announcement regarding its delayed 2025 annual results, noting that its auditor is still collecting documentation and information related to several service agreements and the associated upfront payments needed to complete the annual audit. The company said it will provide further updates on material developments concerning the 2025 results and advised shareholders and potential investors to exercise caution when trading its securities and seek professional advice if uncertain.
The delay in finalizing the audit and publishing the 2025 annual results underscores ongoing information-gathering issues around certain service contracts, which could prolong uncertainty over the company’s financial disclosure timetable. This situation may heighten short-term risk perception among investors and could weigh on market confidence until the audit is completed and full results are released.
The most recent analyst rating on (HK:2898) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.
More about Sunho Biologics,Inc.
Sunho Biologics, Inc. is a biopharmaceutical company listed on the Hong Kong Stock Exchange and incorporated in the Cayman Islands, operating through a group structure referred to as the Group. The company is governed by a board comprising executive, non-executive, and independent non-executive directors, reflecting a typical corporate governance framework for a Hong Kong–listed biotech issuer.
Average Trading Volume: 9,947
Technical Sentiment Signal: Hold
Current Market Cap: HK$970.4M
See more data about 2898 stock on TipRanks’ Stock Analysis page.